1 Features of patients that died for COVID-19 in a Hospital in the south of Mexico: A

2 observational cohort study.

3	Jesús Arturo Ruíz-Quiñonez ^{1#} , Crystell Guadalupe Guzmán-Priego ^{2#} , German
4	Alberto Nolasco-Rosales ² , Carlos Alfonso Tovilla-Zarate ³ , Oscar Israel Flores-
5	Barrientos ¹ , Víctor Narváez-Osorio ¹ , Guadalupe del Carmen Baeza-Flores ² ,
6	Thelma Beatriz Gonzalez-Castro ⁴ , Carlos Ramón López-Brito ¹ , Carlos Alberto
7	Denis-García ¹ , Agustín Pérez-García ¹ , Isela Esther Juárez-Rojop ^{2*} .
8	
9	¹ Hospital de Alta Especialidad Dr. Juan Graham Casasús, Secretaría de Salud,
10	Villahermosa, Tabasco, México.
11	² División Académica de Ciencias de la Salud. Universidad Juárez Autónoma de
12	Tabasco. Villahermosa, Tabasco, México.
13	³ División Académica Multidisciplinaria de Comalcalco, Universidad Juárez
14	Autónoma de Tabasco, Comalcalco, Tabasco, 86650, México.
15	⁴ División Académica de Multidisciplinaria de Jalpa de Méndez, Universidad Juárez
16	Autónoma de Tabasco. Jalpa de Méndez, Tabasco, México.
17	
18	Correspondence to: Isela Esther Juárez-Rojop. Av. Gregorio Méndez Magaña, No
19	2838-A. Col. Tamulté. C.P. 86300, Villahermosa, Tabasco, México. Email:
20	iselajuarezrojop@hotmail.com
21	[#] These authors contributed equally to this work.

22

23 Abstract

Background: Due to the wide spread of SARS-CoV2 around the world, the risk of death in individuals with metabolic comorbidities has dangerously increased. Mexico has a high number of infected individuals and deaths by COVID-19, as well as an important burden of metabolic diseases. However, reports about features of Mexican individuals with COVID-19 are scarce. The aim of this study was to evaluate demographic features, clinical characteristics, and the pharmacological treatment of individuals who died by COVID-19 in the south of Mexico.

Methods: We performed an observational study including 185 deceased individuals with confirmed diagnosis of COVID-19. Data were retrieved from medical records. Categorical data was expressed as proportions (%) and numerical data were expressed as mean ± standard deviation. Comorbidities and overlapping symptoms where plotted as Venn diagrams. Drug clusters were plotted as dendrograms.

Results: The mean age was 59.53 years. There was a male predominance (60.1%).

The mean hospital stay was 4.75 ± 4.43 days. The most frequent symptoms were dyspnea (88.77%), fever (71.42%) and dry cough (64.28%). Present comorbidities were diabetes (60.63%), hypertension (59.57%) and obesity (43.61%). The main drugs used were azithromycin (60.6%), hydroxychloroquine (53.0%) and oseltamivir (27.3%).

42 Conclusions: Mexican individuals who died of COVID-19 had shorter hospital stays,
43 higher frequency of shortness of breath, and higher prevalence of diabetes

44 compared with individuals from other countries. Also, there was a high frequency of

- 45 off-label use of drugs for their treatment.
- 46 **Key word:** COVID-19; SARS-CoV-2, comorbidities; COVID-19 treatment.

47 Introduction

On December 31, 2019, the World Health Organization (WHO) was informed of 48 cases of pneumonia of unknown etiology in Wuhan, China. The Chinese authorities 49 50 identified a new type of coronavirus, which was isolated on January 7, 2020 (1). 51 Coronaviruses are enveloped RNA viruses related to SARS (Severe Acute 52 Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome) 53 coronaviruses. The novel coronavirus was named SARS-CoV2 and COVID-19 is the name of the disease it causes (2, 3). Since it was discovered, SARS-CoV-2 has 54 55 widely spread around the world; by August 15th 2020, there were 21,037,564 56 confirmed cases and 755,455 deaths reported (4).

Up to date, there are some reports and reviews about COVID-19 characteristics in 57 58 individuals from a few populations around the world. These reports agree that the median age of hospitalized individuals is between 47 and 73 years, with a male 59 predominance (60%). Also, the most common symptoms in hospitalized patients are 60 fever (90%), dry cough (60 - 86%), shortness of breath (53 - 80%), fatigue (38%), 61 nausea/vomiting or diarrhea (15 – 39%), and myalgia (15 – 44%). The most frequent 62 comorbidities observed in hospitalized individuals included hypertension (48 - 57%). 63 diabetes (17 - 34%) and cardiovascular diseases (21 - 28%). Comorbidities are 64

65 more common in hospitalized individuals (60 - 90%) compared with the overall 66 infected population (25%) (5).

In Mexico, the first case of COVID-19 was detected on February 27, 2020 (6); whereas on August 15th, there were 505,751 confirmed cases and 55,293 deaths (4). Researches suggest that an important burden of metabolic diseases such as diabetes (10.3%), hypertension (18.4%) and obesity (36.1%) is present in the Mexican population (7), therefore this population could be highly vulnerable to COVID-19.

⁷³ Up to today, there are few reports that include epidemiological data to evaluate ⁷⁴ comorbidities as risk factors in the Mexican population (8, 9). Additionally, we found ⁷⁵ only one report evaluating gastrointestinal symptoms in Mexican patients with ⁷⁶ COVID-19 (10).

We believe it is important to evaluate which pharmacological treatment are used. Although there is not directed antiviral therapy recommended against SARS-CoV-2 (11-13), in our sample some off-label drugs were administrated regardless of what has been observed in clinical trials, particularly at the beginning of the pandemic. Therefore, our aim was to evaluate demographic features, clinical characteristics, and pharmacological treatment received by individuals who died by COVID-19 in a third level hospital in the south of Mexico.

84

85 Methods

86 This was an observational retrospective study performed at the High Specialty Regional Hospital "Dr. Juan Graham Casasús" (HJGC) in Villahermosa, Tabasco, 87 Mexico. We used the medical records of every individual with COVID-19 as the 88 cause of death, who was admitted to the HJGC from April 15th to May 12th, 2020. 89 These individuals had been diagnosed with COVID-19 by epidemiologists following 90 the Mexican Health Secretary's guidelines; additionally, they tested positive for 91 SARS-CoV-2 by Reverse Transcriptase Polymerase Chain Reaction. The ethical 92 approval was granted by the Research Ethics Committee of the Juárez Autonomous 93 94 University of Tabasco (103/CIP-DACS/2020) in Mexico.

Three physician doctors retrieved data from clinical files after patients' death. Data collected included age, gender, clinical symptoms, underlying comorbidities, length of hospital stay, and drugs used as COVID-19 treatment.

We performed a descriptive report. Numerical data was expressed as mean ± standard deviation and proportions (%) for categorical data. Gender, age and comorbidities were compared using the Chi-squared test, with significance of p = 0.05. Comorbidities and overlapping symptoms where plotted as Venn diagrams. Drug clusters were plotted as dendrograms. All data were analyzed using SPSS v.23.

104

105 **Results.**

In this study, the files of 185 deceased individuals were included; these individuals
 had been diagnosed and treated for COVID-19 between April 15 and May 12, 2020

at the HJGC in Villahermosa Tabasco, Mexico. The length of time in hospital was
4.75 days in means (S.D. 4.43). The distribution of days of hospitalization by gender
is shown in Fig 1.

Fig 1. Individuals who died of COVID-19 stratified by gender and days of hospitalization.

113

Age and Gender

115 The mean age of the individuals studied was 59.53±12.50 (range 24-86) years.

116 When we stratified them by age, the majority of deaths occurred in individuals 65+

117 years (36.7%, n=58). Nevertheless, the groups of 55 and 65+ years constituted

118 67.7% of the sample (n=107). The comparison between males and females is shown

in Table 1. No significant differences were observed between groups in terms of age.

120	Table 1. Characteristics stratified by gender of individuals who died of
121	COVID-19.

	All	Male	Female	X ² , p
Total	158	95 (60.1)	63 (39.9)	
Age				4.36, 0.35
24-34	5 (3.2)	3 (3.2)	2 (3.2)	
35-44	13 (8.2)	9 (9.5)	4 (6.3)	
44-54	33 (20.9)	24 (25.3)	9 (14.3)	
55-64	49 (31.0	29 (30.5)	20 (31.7)	
65+	58 (36.7)	30 (31.6)	28 (44.4)	
Any				2.55, 0.11
comorbidity				
Yes	101 (63.9)	56 (58.9)	(45 (71.4)	
No or not	57 (36.1)	39 (41.1)	18 (28.6)	
reported				
Type 2	56 (35.4)	27 (27.4)	29 (46.0)	1.83, 0.17
Diabetes-Yes				
Obesity-Yes	41 (25.9)	21 (22.1)	20 (31.7)	5.13, 0.12

Hypertension- Yes	56 (35.4)	31 (32.6)	25 (39.7)	0.82, 0.36
----------------------	-----------	-----------	-----------	------------

122

123 Symptoms

124 The most common symptoms on admission were shortness of breath (overall: 88.77%; males: 55.2%, females: 44.8%), fever (overall: 71.42%, males: 51.4%, 125 females: 48.6%), dry cough (overall: 64.28%: males: 58.7%, females: 41.3%), 126 127 headache (overall: 43.87%, males: 55.8%, females: 44.2%), and myalgia (overall: 34.69%, males: 44.1%, females: 55.9%). When overlapping symptoms were 128 observed, the first cluster included fever, dry cough, shortness of breath and 129 headache. Other cluster was fever, dry cough, shortness of breath, myalgia, 130 arthralgia and headache. Then fever, dry cough, shortness of breath, myalgia and 131 132 arthralgia without headache. And fever and shortness of breath (Fig 2).

Fig 2. Venn diagram of overlapping symptoms. We plotted overlaps between the three main symptoms found in the sample. The higher proportions were fever or cough only, without manifestation of another symptom. The largest overlap was the triad fever-cough-dyspnea. Then, in order of frequency the main overlaps were fever-dyspnea and cough-dyspnea.

138

139 **Comorbidities**

140 The most common comorbidities on admission were Type 2 Diabetes (60.63%), 141 hypertension (59.57%) and obesity (43.61%). The main overlap between these comorbidities were T2D-Hypertensión. The second cluster was T2DMHypertension-Obesity and finally Hypertension-Obesity (Fig 3).

Fig 3. Venn diagram of overlapping comorbidities. The main overlap was the dyad Hypertension-T2D. The frequency of these comorbidities alone was almost equal. The next overlaps in order of frequency were the triad Hypertension-T2D-Obesity and the dyad Hypertension-Obesity.

148 Pharmacological therapy

The most frequent drugs used for treating individuals with COVID-19 were azithromycin (60.6%) and hydroxychloroquine (53%). Less frequently employed were oseltamivir (27.3%), tocilizumab (16.77%) and lopinavir-ritonavir (16.7%). Drugs for various purposes (e.g. paracetamol, dexamethasone) were grouped as others, these were given to 66.7% of the patients.

154 Clustering drugs. We observed that azithromycin and hydroxychloroquine were 155 frequently given together, followed by lopinavir-ritonavir with tocilizumab, and 156 oseltamivir with lopinavir-ritonavir or tocilizumab (Fig 4).

Fig 4. Dendrogram of relationships between drugs used. The closest relation
was azithromycin – hydroxychloroquine, followed by oseltamivir – lopinavir or
tocilizumab.

160

161 **Discussion**

In this study, we gathered clinical and demographic characteristics of individuals who
 died of COVID-19; we also identified drugs that were most used as antiviral
 treatment in those individuals.

There were 60% of male individuals. Gender consistency was an expected statistic as COVID-19 shows male predominance in Mexico's epidemiological data (8), as well as in other populations (5, 14-16). We found that 67.7% of individuals were \geq 55 years old. Although age varies widely among reports, our results are comparable to samples from patients with severe COVID-19 (14, 17). The mean length time hospitalized in days was 4.75 ± 4.43, which is shorter than what was reported in an observational study of fatal cases from Wuhan, China (6.35 ± 4.51) (17).

Shortness of breath, fever and dry cough were the most prevalent symptoms in our 172 sample. Fever and cough had been reported as the most prevalent symptoms in 173 several studies, including the Mexican population and severe cases (5, 10, 15, 17-174 175 19). On the other hand, the third most prevalent symptom varies widely; for instance, a review found dyspnea prevalence of 53 - 80%, and a series of fatal cases found 176 in 70.6% (5, 17). Nonetheless, in clinical series and meta-analysis involving non-177 lethal cases, the third most prevalent symptom was myalgias or fatigue (31-67%) 178 (10, 15, 18, 19). In our sample, shortness of breath was the most prevalent symptom 179 180 and it was present in every cluster of symptoms, which could indicate that shortness of breath is an early symptom and bad prognosis. 181

The most common comorbidities in our sample were type 2 diabetes, hypertension and obesity. Remarkably, diabetes and hypertension had similar frequencies. In Mexican individuals with COVID-19, it is reported a slightly higher frequency of

185 hypertension compared with diabetes (8, 10). Nonetheless, in other populations hypertension has a much higher prevalence compared to diabetes (5, 18). In two 186 meta-analyses from the same work group (20, 21), hypertension and diabetes were 187 188 associated with poor outcomes in COVID-19. The hypertension association was influenced by gender, but not by age or diabetes, while the diabetes association was 189 influenced by age and hypertension. On the other hand, in a study using 190 OpenSAFELY database (16), hypertension was associated with an increased risk 191 (HR 1.09) but it could not be associated when the risk was adjusted to age, gender, 192 193 diabetes and obesity. In addition, diabetes and obesity were associated with an increased risk of death (HR 1.90 and 1.92, respectively). Furthermore, 194 epidemiological data of COVID-19 in Mexico, indicates that obesity is a risk factor 195 196 for death and is a partial mediator on the effects of diabetes in decreased survival (8). Finally, when comorbidities in our sample were clustered, we observed a lower 197 frequency of individuals with only-hypertension compared with only-diabetes and 198 only-obesity patients. Therefore, diabetes and obesity should not be overlooked as 199 strong risk factors and poor outcomes. 200

In our sample, the most frequent treatment was hydroxychloroquine associated with azithromycin. Although there is evidence of in vitro activity against SARS-CoV-2, the use of hydroxychloroquine and azithromycin for clinical benefit is supported by limited and conflicting clinical data (22). Antiviral agents were next in frequency order. Oseltamivir was the third most administrated treatment. However, there are no reports about oseltamivir having in vitro activity against SARS-CoV-2. Although some clinical trials include oseltamivir, it is not proposed as therapeutic intervention

208 (23). Lopinavir-ritonavir was less frequently used as treatment in our sample; while it is reported in vitro activity against SARS-CoV-2, clinical trials have failed in 209 associate it with better clinical outcomes (24). Finally, the only immunomodulatory 210 211 drug used in our sample was tocilizumab. In a meta-analysis, tocilizumab was associated with a significant decrease in mortality rate and ameliorate clinical 212 symptoms in patients with COVID-19 (25). Despite of its promising results, 213 immunomodulatory drugs access is limited and it is not broadly used in clinical 214 settings in Mexico. 215

Our study has some limitations. First, we had limited information about some individuals because they died within minutes after their arrival to the emergency room. Second, we did not include surviving individuals so we could not compare characteristics between groups. Third, we included data of only one frontline hospital for treating COVID-19. Consequently, this report shows characteristics and handling of patients at the beginning of the COVID-19 pandemic at the south of Mexico; therefore, our data cannot be applied to the whole Mexican population.

In conclusion, our study showed a high frequency of off-label use of drugs that have insufficient evidence of their efficacy against COVID-19. The individuals in our sample had shorter hospital stays, higher frequency of shortness of breath, and higher prevalence of diabetes compared with similar populations from other countries. It is important to do more clinical series and cohorts in Mexican population, as this population shows features that could differ of populations of other countries.

229

230 **References**

231

- 1. World Health Organization. Situation Report 1 [Internet]. Geneva: World
- Health Organization; 2020 [updated 01/20/2020; cited 2020 Jul 6]. Available from:
- 234 <u>https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-</u>
- 235 <u>sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4</u>.

2020

- 236 2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus
- from Patients with Pneumonia in China, 2019. New England Journal of Medicine.
- 238 2020;382(8):727-33.

[updated

3. World Health Organization. Naming the coronavirus disease (COVID-19) and

the virus that causes it. [Internet]. Geneva: World Health Organization; 2020

cited

2020

Jul

5].

Available

from:

242 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-

11;

Feb

- 243 guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-
- 244 <u>it</u>.

241

4. WHO coronavirus disease (COVID-19) dashboard. [Internet]. World Health
Organization. 2020 [cited 2020 Aug 25]. Available from: <u>https://covid19.who.int/</u>.

Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC.
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease
2019 (COVID-19): A Review. JAMA. 2020; doi: 10.1001/jama.2020.12839.

- 250 6. Suárez V, Suarez Quezada M, Oros Ruiz S, Ronquillo De Jesús E.
 251 Epidemiología de COVID-19 en México: del 27 de febrero al 30 de abril de 2020.
- 252 Revista Clínica Española. 2020; doi: 10.1016/j.rce.2020.05.007.

253 7. Instituto Nacional de Estadística y Geografía. Encuesta Nacional de Salud y

254 Nutrición (ENSANUT) 2018 [Internet]. Mexico City: Instituto Nacional de Estadística

y Geografía; 2018 [updated 2020 Apr 20; cited 2020 Jul 14]. Available from:

256 <u>https://www.inegi.org.mx/programas/ensanut/2018/default.html#Documentacion.</u>

8. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A,

258 González-Díaz A, Márquez-Salinas A, et al. Predicting Mortality Due to SARS-CoV-

259 2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in
260 Mexico. The Journal of Clinical Endocrinology & Metabolism. 2020;105(8).

9. Kammar-García A, Vidal-Mayo JJ, Vera-Zertuche JM, Lazcano-Hernández
 M, Vera-López O, Segura-Badilla O, et al. Impact of Comorbidities in Mexican
 SARS-CoV-2-Positive Patients: A Restrospective Analysis in a National Cohort.
 Revista de investigacion clinica; organo del Hospital de Enfermedades de la
 Nutricion. 2020;72(3):151-8.

Remes-Troche JM, Ramos-de-la-Medina A, Manríquez-Reyes M, Martínez Pérez-Maldonado L, Lara EL, Solís-González MA. Initial Gastrointestinal
 Manifestations in Patients with SARS-CoV-2 in 112 patients from Veracruz
 (Southeastern Mexico). Gastroenterology. 2020; doi:
 10.1053/j.gastro.2020.05.055:S0016-5085(20)34708-9.

11. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving
Sepsis Campaign: guidelines on the management of critically ill adults with
Coronavirus Disease 2019 (COVID-19). Intensive Care Medicine. 2020;46(5):85487.

12. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID19) Treatment Guidelines [Internet]. Bethesda: National Institutes of Health; 2020

- 277 [cited 2020 Jul 26]. Available from:
 278 https://www.covid19treatmentguidelines.nih.gov/.
- 13. Secretaría de Salud. Recomendaciones para el tratamiento de la infección
- por SARS-CoV2, agente causal de COVID-19. [Internet]. Mexico City: Secretaría de
- 281 Salud; 2020 [updated 07/06/2020; cited 2020 07/26]. Available from:
- 282 <u>https://coronavirus.gob.mx/wp-</u>
- 283 content/uploads/2020/07/Recomendaciones para tratamiento SARS-CoV2.pdf.
- 14. Yu Y, Xu D, Fu S, Zhang J, Yang X, Xu L, et al. Patients with COVID-19 in 19
- ICUs in Wuhan, China: a cross-sectional study. Critical Care. 2020;24(1):219.
- 15. Li L-q, Huang T, Wang Y-q, Wang Z-p, Liang Y, Huang T-b, et al. COVID-19
- patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis.
- 288 Journal of Medical Virology. 2020;92(6):577-83.
- 16. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al.
- Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;
 doi: 10.1038/s41586-020-2521-4.
- Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical Features of 85 Fatal
 Cases of COVID-19 from Wuhan. A Retrospective Observational Study. American
 Journal of Respiratory and Critical Care Medicine. 2020;201(11):1372-9.
- 18. Tahvildari A, Arbabi M, Farsi Y, Jamshidi P, Hasanzadeh S, Calcagno TM, et
 al. Clinical Features, Diagnosis, and Treatment of COVID-19 in Hospitalized
 Patients: A Systematic Review of Case Reports and Case Series. Frontiers in
 Medicine. 2020;7:231.
- 19. Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL,
 et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus

301 (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies
 302 from 9 countries. PLOS ONE. 2020;15(6):e0234765.

Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased
mortality and severity of disease in COVID-19 pneumonia – A systematic review,
meta-analysis, and meta-regression. Diabetes & Metabolic Syndrome: Clinical
Research & Reviews. 2020;14(4):395-403.

Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is
associated with increased mortality and severity of disease in COVID-19 pneumonia:
A systematic review, meta-analysis and meta-regression. Journal of the ReninAngiotensin-Aldosterone System. 2020;21(2):1470320320926899.

Vijayvargiya P, Esquer Garrigos Z, Castillo Almeida NE, Gurram PR, Stevens
RW, Razonable RR. Treatment Considerations for COVID-19: A Critical Review of
the Evidence (or Lack Thereof). Mayo Clinic Proceedings. 2020;95(7):1454-66.

314 23. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic
315 Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA.
316 2020;323(18):1824-36.

317 24. Kotwani A, Gandra S. Potential pharmacological agents for COVID-19. Indian
318 J Public Health. 2020;64(6):112-6.

Talaie H, Hosseini SM, Nazari M, Fakhri Y, Mousavizadeh A, Vatanpour H, et 25. 319 320 al. Is there any potential management against COVID-19? A systematic review and DARU Journal of Pharmaceutical Sciences. 2020; doi: 321 meta-analysis. 10.1007/s40199-020-00367-4. 322

323